Immune dysregulation in cancer patients developing immune-related adverse events
Cancer immunotherapy has revolutionised the treatment of multiple malignancies, with approvals in melanoma, lung cancer, bladder cancer, head and neck cancer, lymphoma, kidney cancer, Merkel cell tumours and microsatellite instability-high cancers. While these promising drugs have led to improved outcomes for thousands of patients, they have also introduced new safety concerns.
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
